BRAF V600E mutation - Revision history

Michael at 21:11, 30 June 2024

2024-06-30T21:11:46Z

← Older revision		Revision as of 21:11, 30 June 2024
Line 21:		Line 21:
	===Less commonly mutated===		===Less commonly mutated===
	*[[Colorectal cancer]] (5.5%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>		*[[Colorectal cancer]] (5.5%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>
	**Associated with MSI - specifically MLH1 loss in MMR testing.<ref name=pmid25386108>{{cite journal \|authors=Zaanan A, Bachet JB, André T, Sinicrope FA \|title=Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAFV600E in Patients with Lymph Node-Positive Colon Cancer \|journal=Curr Colorectal Cancer Rep \|volume=10 \|issue=3 \|pages=346–353 \|date=September 2014 \|pmid=25386108 \|pmc=4224319 \|doi=10.1007/s11888-014-0237-2 \|url=}}</ref>		**Associated with MSI - specifically MLH1 loss in [[MMR testing]].<ref name=pmid25386108>{{cite journal \|authors=Zaanan A, Bachet JB, André T, Sinicrope FA \|title=Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAFV600E in Patients with Lymph Node-Positive Colon Cancer \|journal=Curr Colorectal Cancer Rep \|volume=10 \|issue=3 \|pages=346–353 \|date=September 2014 \|pmid=25386108 \|pmc=4224319 \|doi=10.1007/s11888-014-0237-2 \|url=}}</ref>
	*[[Ovarian cancer]] (7%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>		*[[Ovarian cancer]] (7%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>
	*[[Lung adenocarcinoma]] (5%).<ref name=pmid23131393>{{Cite journal \| last1 = Ilie \| first1 = M. \| last2 = Long \| first2 = E. \| last3 = Hofman \| first3 = V. \| last4 = Dadone \| first4 = B. \| last5 = Marquette \| first5 = CH. \| last6 = Mouroux \| first6 = J. \| last7 = Vignaud \| first7 = JM. \| last8 = Begueret \| first8 = H. \| last9 = Merlio \| first9 = JP. \| title = Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. \| journal = Ann Oncol \| volume = 24 \| issue = 3 \| pages = 742-8 \| month = Mar \| year = 2013 \| doi = 10.1093/annonc/mds534 \| PMID = 23131393 }}</ref>		*[[Lung adenocarcinoma]] (5%).<ref name=pmid23131393>{{Cite journal \| last1 = Ilie \| first1 = M. \| last2 = Long \| first2 = E. \| last3 = Hofman \| first3 = V. \| last4 = Dadone \| first4 = B. \| last5 = Marquette \| first5 = CH. \| last6 = Mouroux \| first6 = J. \| last7 = Vignaud \| first7 = JM. \| last8 = Begueret \| first8 = H. \| last9 = Merlio \| first9 = JP. \| title = Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. \| journal = Ann Oncol \| volume = 24 \| issue = 3 \| pages = 742-8 \| month = Mar \| year = 2013 \| doi = 10.1093/annonc/mds534 \| PMID = 23131393 }}</ref>

Michael at 21:11, 30 June 2024

2024-06-30T21:11:24Z

← Older revision		Revision as of 21:11, 30 June 2024
Line 21:		Line 21:
	===Less commonly mutated===		===Less commonly mutated===
	*[[Colorectal cancer]] (5.5%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>		*[[Colorectal cancer]] (5.5%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>
			**Associated with MSI - specifically MLH1 loss in MMR testing.<ref name=pmid25386108>{{cite journal \|authors=Zaanan A, Bachet JB, André T, Sinicrope FA \|title=Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAFV600E in Patients with Lymph Node-Positive Colon Cancer \|journal=Curr Colorectal Cancer Rep \|volume=10 \|issue=3 \|pages=346–353 \|date=September 2014 \|pmid=25386108 \|pmc=4224319 \|doi=10.1007/s11888-014-0237-2 \|url=}}</ref>
	*[[Ovarian cancer]] (7%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>		*[[Ovarian cancer]] (7%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>
	*[[Lung adenocarcinoma]] (5%).<ref name=pmid23131393>{{Cite journal \| last1 = Ilie \| first1 = M. \| last2 = Long \| first2 = E. \| last3 = Hofman \| first3 = V. \| last4 = Dadone \| first4 = B. \| last5 = Marquette \| first5 = CH. \| last6 = Mouroux \| first6 = J. \| last7 = Vignaud \| first7 = JM. \| last8 = Begueret \| first8 = H. \| last9 = Merlio \| first9 = JP. \| title = Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. \| journal = Ann Oncol \| volume = 24 \| issue = 3 \| pages = 742-8 \| month = Mar \| year = 2013 \| doi = 10.1093/annonc/mds534 \| PMID = 23131393 }}</ref>		*[[Lung adenocarcinoma]] (5%).<ref name=pmid23131393>{{Cite journal \| last1 = Ilie \| first1 = M. \| last2 = Long \| first2 = E. \| last3 = Hofman \| first3 = V. \| last4 = Dadone \| first4 = B. \| last5 = Marquette \| first5 = CH. \| last6 = Mouroux \| first6 = J. \| last7 = Vignaud \| first7 = JM. \| last8 = Begueret \| first8 = H. \| last9 = Merlio \| first9 = JP. \| title = Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. \| journal = Ann Oncol \| volume = 24 \| issue = 3 \| pages = 742-8 \| month = Mar \| year = 2013 \| doi = 10.1093/annonc/mds534 \| PMID = 23131393 }}</ref>

Michael: vauthors - fix

2021-03-25T17:18:56Z

vauthors - fix

← Older revision		Revision as of 17:18, 25 March 2021
Line 23:		Line 23:
	*[[Ovarian cancer]] (7%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>		*[[Ovarian cancer]] (7%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>
	*[[Lung adenocarcinoma]] (5%).<ref name=pmid23131393>{{Cite journal \| last1 = Ilie \| first1 = M. \| last2 = Long \| first2 = E. \| last3 = Hofman \| first3 = V. \| last4 = Dadone \| first4 = B. \| last5 = Marquette \| first5 = CH. \| last6 = Mouroux \| first6 = J. \| last7 = Vignaud \| first7 = JM. \| last8 = Begueret \| first8 = H. \| last9 = Merlio \| first9 = JP. \| title = Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. \| journal = Ann Oncol \| volume = 24 \| issue = 3 \| pages = 742-8 \| month = Mar \| year = 2013 \| doi = 10.1093/annonc/mds534 \| PMID = 23131393 }}</ref>		*[[Lung adenocarcinoma]] (5%).<ref name=pmid23131393>{{Cite journal \| last1 = Ilie \| first1 = M. \| last2 = Long \| first2 = E. \| last3 = Hofman \| first3 = V. \| last4 = Dadone \| first4 = B. \| last5 = Marquette \| first5 = CH. \| last6 = Mouroux \| first6 = J. \| last7 = Vignaud \| first7 = JM. \| last8 = Begueret \| first8 = H. \| last9 = Merlio \| first9 = JP. \| title = Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. \| journal = Ann Oncol \| volume = 24 \| issue = 3 \| pages = 742-8 \| month = Mar \| year = 2013 \| doi = 10.1093/annonc/mds534 \| PMID = 23131393 }}</ref>
	*Endosalpingiosis, especially those with synchronous or metachronous low grade serous neoplasms (up to 8/21).<ref>{{cite journal \|~~vauthors~~=Chui MH, Shih IM \|title=Oncogenic BRAF and KRAS mutations in endosalpingiosis \|journal=J Pathol \|volume=250 \|issue=2 \|pages=148–158 \|date=February 2020 \|pmid=31576556 \|doi=10.1002/path.5353 \|url=}}</ref>		*Endosalpingiosis, especially those with synchronous or metachronous low grade serous neoplasms (up to 8/21).<ref>{{cite journal \|authors=Chui MH, Shih IM \|title=Oncogenic BRAF and KRAS mutations in endosalpingiosis \|journal=J Pathol \|volume=250 \|issue=2 \|pages=148–158 \|date=February 2020 \|pmid=31576556 \|doi=10.1002/path.5353 \|url=}}</ref>

	==See also==		==See also==

Mark: more detail about endosalpingiosis

2020-11-15T11:17:43Z

more detail about endosalpingiosis

← Older revision		Revision as of 11:17, 15 November 2020
Line 23:		Line 23:
	*[[Ovarian cancer]] (7%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>		*[[Ovarian cancer]] (7%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>
	*[[Lung adenocarcinoma]] (5%).<ref name=pmid23131393>{{Cite journal \| last1 = Ilie \| first1 = M. \| last2 = Long \| first2 = E. \| last3 = Hofman \| first3 = V. \| last4 = Dadone \| first4 = B. \| last5 = Marquette \| first5 = CH. \| last6 = Mouroux \| first6 = J. \| last7 = Vignaud \| first7 = JM. \| last8 = Begueret \| first8 = H. \| last9 = Merlio \| first9 = JP. \| title = Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. \| journal = Ann Oncol \| volume = 24 \| issue = 3 \| pages = 742-8 \| month = Mar \| year = 2013 \| doi = 10.1093/annonc/mds534 \| PMID = 23131393 }}</ref>		*[[Lung adenocarcinoma]] (5%).<ref name=pmid23131393>{{Cite journal \| last1 = Ilie \| first1 = M. \| last2 = Long \| first2 = E. \| last3 = Hofman \| first3 = V. \| last4 = Dadone \| first4 = B. \| last5 = Marquette \| first5 = CH. \| last6 = Mouroux \| first6 = J. \| last7 = Vignaud \| first7 = JM. \| last8 = Begueret \| first8 = H. \| last9 = Merlio \| first9 = JP. \| title = Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. \| journal = Ann Oncol \| volume = 24 \| issue = 3 \| pages = 742-8 \| month = Mar \| year = 2013 \| doi = 10.1093/annonc/mds534 \| PMID = 23131393 }}</ref>
	*Endosalpingiosis<ref>{{cite journal \|vauthors=Chui MH, Shih IM \|title=Oncogenic BRAF and KRAS mutations in endosalpingiosis \|journal=J Pathol \|volume=250 \|issue=2 \|pages=148–158 \|date=February 2020 \|pmid=31576556 \|doi=10.1002/path.5353 \|url=}}</ref>		*Endosalpingiosis, especially those with synchronous or metachronous low grade serous neoplasms (up to 8/21).<ref>{{cite journal \|vauthors=Chui MH, Shih IM \|title=Oncogenic BRAF and KRAS mutations in endosalpingiosis \|journal=J Pathol \|volume=250 \|issue=2 \|pages=148–158 \|date=February 2020 \|pmid=31576556 \|doi=10.1002/path.5353 \|url=}}</ref>

	==See also==		==See also==

Mark: endosalpingiosis

2020-11-15T10:13:07Z

endosalpingiosis

← Older revision		Revision as of 10:13, 15 November 2020
Line 23:		Line 23:
	*[[Ovarian cancer]] (7%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>		*[[Ovarian cancer]] (7%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>
	*[[Lung adenocarcinoma]] (5%).<ref name=pmid23131393>{{Cite journal \| last1 = Ilie \| first1 = M. \| last2 = Long \| first2 = E. \| last3 = Hofman \| first3 = V. \| last4 = Dadone \| first4 = B. \| last5 = Marquette \| first5 = CH. \| last6 = Mouroux \| first6 = J. \| last7 = Vignaud \| first7 = JM. \| last8 = Begueret \| first8 = H. \| last9 = Merlio \| first9 = JP. \| title = Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. \| journal = Ann Oncol \| volume = 24 \| issue = 3 \| pages = 742-8 \| month = Mar \| year = 2013 \| doi = 10.1093/annonc/mds534 \| PMID = 23131393 }}</ref>		*[[Lung adenocarcinoma]] (5%).<ref name=pmid23131393>{{Cite journal \| last1 = Ilie \| first1 = M. \| last2 = Long \| first2 = E. \| last3 = Hofman \| first3 = V. \| last4 = Dadone \| first4 = B. \| last5 = Marquette \| first5 = CH. \| last6 = Mouroux \| first6 = J. \| last7 = Vignaud \| first7 = JM. \| last8 = Begueret \| first8 = H. \| last9 = Merlio \| first9 = JP. \| title = Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. \| journal = Ann Oncol \| volume = 24 \| issue = 3 \| pages = 742-8 \| month = Mar \| year = 2013 \| doi = 10.1093/annonc/mds534 \| PMID = 23131393 }}</ref>
			*Endosalpingiosis<ref>{{cite journal \|vauthors=Chui MH, Shih IM \|title=Oncogenic BRAF and KRAS mutations in endosalpingiosis \|journal=J Pathol \|volume=250 \|issue=2 \|pages=148–158 \|date=February 2020 \|pmid=31576556 \|doi=10.1002/path.5353 \|url=}}</ref>

	==See also==		==See also==

Mark: metanephric adenoma

2019-01-24T23:05:26Z

metanephric adenoma

← Older revision		Revision as of 23:05, 24 January 2019
Line 17:		Line 17:
	*[[Hairy cell leukemia]] (>90%)		*[[Hairy cell leukemia]] (>90%)
	*Histiocytic disorders: [[Langerhans cell histiocytosis]] and [[Erdheim-Chester disease]]		*Histiocytic disorders: [[Langerhans cell histiocytosis]] and [[Erdheim-Chester disease]]
			*Metanephric adenoma <ref name=pmid22727996>{{Cite journal \| last1 = Choueiri \| first1 = TK. \| last2 = Cheville \| first2 = J. \| last3 = Palescandolo \| first3 = E. \| last4 = Fay \| first4 = AP. \| last5 = Kantoff \| first5 = PW. \| last6 = Atkins \| first6 = MB. \| last7 = McKenney \| first7 = JK. \| last8 = Brown \| first8 = V. \| last9 = Lampron \| first9 = ME. \| title = BRAF mutations in metanephric adenoma of the kidney. \| journal = Eur Urol \| volume = 62 \| issue = 5 \| pages = 917-22 \| month = Nov \| year = 2012 \| doi = 10.1016/j.eururo.2012.05.051 \| PMID = 22727996 }}</ref><ref name=pmid25602792>{{Cite journal \| last1 = Udager \| first1 = AM. \| last2 = Pan \| first2 = J. \| last3 = Magers \| first3 = MJ. \| last4 = Palapattu \| first4 = GS. \| last5 = Morgan \| first5 = TM. \| last6 = Montgomery \| first6 = JS. \| last7 = Weizer \| first7 = AZ. \| last8 = Hafez \| first8 = KS. \| last9 = Miller \| first9 = DC. \| title = Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma. \| journal = Am J Surg Pathol \| volume = 39 \| issue = 4 \| pages = 549-57 \| month = Apr \| year = 2015 \| doi = 10.1097/PAS.0000000000000377 \| PMID = 25602792 }}</ref>

	===Less commonly mutated===		===Less commonly mutated===

Michael at 18:19, 23 January 2019

2019-01-23T18:19:57Z

← Older revision		Revision as of 18:19, 23 January 2019
Line 2:		Line 2:
	The '''BRAF V600E mutation''', also '''BRAF V600E''', is a common recurrent mutation in the BRAF gene that is seen in many types of tumours and [[cancer]].<ref name=pmid21638088/>		The '''BRAF V600E mutation''', also '''BRAF V600E''', is a common recurrent mutation in the BRAF gene that is seen in many types of tumours and [[cancer]].<ref name=pmid21638088/>

			A more general discussion about ''BRAF'' is in ''[[BRAF mutation]]''.

			==General==
	The ''BRAF gene'', formally known as ''v-RAF murine sarcoma viral oncogene homolog B1'', is a serine threonine kinase.<ref>{{OMIM\|164757}}</ref>		The ''BRAF gene'', formally known as ''v-RAF murine sarcoma viral oncogene homolog B1'', is a serine threonine kinase.<ref>{{OMIM\|164757}}</ref>

Michael at 18:17, 23 January 2019

2019-01-23T18:17:14Z

← Older revision		Revision as of 18:17, 23 January 2019
Line 25:		Line 25:
	*[[KRAS mutation]].		*[[KRAS mutation]].
	*[[Cancer Hotspot Panel v2]].		*[[Cancer Hotspot Panel v2]].
			*[[BRAF mutation]].

	==References==		==References==

Michael: /* See also */

2018-12-28T16:20:34Z

Michael: /* See also */

2018-12-28T16:19:49Z

← Older revision		Revision as of 21:11, 30 June 2024
Line 21:		Line 21:
	===Less commonly mutated===		===Less commonly mutated===
	*[[Colorectal cancer]] (5.5%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>		*[[Colorectal cancer]] (5.5%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>
	**Associated with MSI - specifically MLH1 loss in MMR testing.<ref name=pmid25386108>{{cite journal \|authors=Zaanan A, Bachet JB, André T, Sinicrope FA \|title=Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAFV600E in Patients with Lymph Node-Positive Colon Cancer \|journal=Curr Colorectal Cancer Rep \|volume=10 \|issue=3 \|pages=346–353 \|date=September 2014 \|pmid=25386108 \|pmc=4224319 \|doi=10.1007/s11888-014-0237-2 \|url=}}</ref>		**Associated with MSI - specifically MLH1 loss in [[MMR testing]].<ref name=pmid25386108>{{cite journal \|authors=Zaanan A, Bachet JB, André T, Sinicrope FA \|title=Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAFV600E in Patients with Lymph Node-Positive Colon Cancer \|journal=Curr Colorectal Cancer Rep \|volume=10 \|issue=3 \|pages=346–353 \|date=September 2014 \|pmid=25386108 \|pmc=4224319 \|doi=10.1007/s11888-014-0237-2 \|url=}}</ref>
	*[[Ovarian cancer]] (7%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>		*[[Ovarian cancer]] (7%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>
	*[[Lung adenocarcinoma]] (5%).<ref name=pmid23131393>{{Cite journal \| last1 = Ilie \| first1 = M. \| last2 = Long \| first2 = E. \| last3 = Hofman \| first3 = V. \| last4 = Dadone \| first4 = B. \| last5 = Marquette \| first5 = CH. \| last6 = Mouroux \| first6 = J. \| last7 = Vignaud \| first7 = JM. \| last8 = Begueret \| first8 = H. \| last9 = Merlio \| first9 = JP. \| title = Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. \| journal = Ann Oncol \| volume = 24 \| issue = 3 \| pages = 742-8 \| month = Mar \| year = 2013 \| doi = 10.1093/annonc/mds534 \| PMID = 23131393 }}</ref>		*[[Lung adenocarcinoma]] (5%).<ref name=pmid23131393>{{Cite journal \| last1 = Ilie \| first1 = M. \| last2 = Long \| first2 = E. \| last3 = Hofman \| first3 = V. \| last4 = Dadone \| first4 = B. \| last5 = Marquette \| first5 = CH. \| last6 = Mouroux \| first6 = J. \| last7 = Vignaud \| first7 = JM. \| last8 = Begueret \| first8 = H. \| last9 = Merlio \| first9 = JP. \| title = Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. \| journal = Ann Oncol \| volume = 24 \| issue = 3 \| pages = 742-8 \| month = Mar \| year = 2013 \| doi = 10.1093/annonc/mds534 \| PMID = 23131393 }}</ref>

← Older revision		Revision as of 21:11, 30 June 2024
Line 21:		Line 21:
	===Less commonly mutated===		===Less commonly mutated===
	*[[Colorectal cancer]] (5.5%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>		*[[Colorectal cancer]] (5.5%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>
			**Associated with MSI - specifically MLH1 loss in MMR testing.<ref name=pmid25386108>{{cite journal \|authors=Zaanan A, Bachet JB, André T, Sinicrope FA \|title=Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAFV600E in Patients with Lymph Node-Positive Colon Cancer \|journal=Curr Colorectal Cancer Rep \|volume=10 \|issue=3 \|pages=346–353 \|date=September 2014 \|pmid=25386108 \|pmc=4224319 \|doi=10.1007/s11888-014-0237-2 \|url=}}</ref>
	*[[Ovarian cancer]] (7%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>		*[[Ovarian cancer]] (7%).<ref name=pmid22012135>{{Cite journal \| last1 = Capper \| first1 = D. \| last2 = Berghoff \| first2 = AS. \| last3 = Magerle \| first3 = M. \| last4 = Ilhan \| first4 = A. \| last5 = Wöhrer \| first5 = A. \| last6 = Hackl \| first6 = M. \| last7 = Pichler \| first7 = J. \| last8 = Pusch \| first8 = S. \| last9 = Meyer \| first9 = J. \| title = Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. \| journal = Acta Neuropathol \| volume = 123 \| issue = 2 \| pages = 223-33 \| month = Feb \| year = 2012 \| doi = 10.1007/s00401-011-0887-y \| PMID = 22012135 }}</ref>
	*[[Lung adenocarcinoma]] (5%).<ref name=pmid23131393>{{Cite journal \| last1 = Ilie \| first1 = M. \| last2 = Long \| first2 = E. \| last3 = Hofman \| first3 = V. \| last4 = Dadone \| first4 = B. \| last5 = Marquette \| first5 = CH. \| last6 = Mouroux \| first6 = J. \| last7 = Vignaud \| first7 = JM. \| last8 = Begueret \| first8 = H. \| last9 = Merlio \| first9 = JP. \| title = Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. \| journal = Ann Oncol \| volume = 24 \| issue = 3 \| pages = 742-8 \| month = Mar \| year = 2013 \| doi = 10.1093/annonc/mds534 \| PMID = 23131393 }}</ref>		*[[Lung adenocarcinoma]] (5%).<ref name=pmid23131393>{{Cite journal \| last1 = Ilie \| first1 = M. \| last2 = Long \| first2 = E. \| last3 = Hofman \| first3 = V. \| last4 = Dadone \| first4 = B. \| last5 = Marquette \| first5 = CH. \| last6 = Mouroux \| first6 = J. \| last7 = Vignaud \| first7 = JM. \| last8 = Begueret \| first8 = H. \| last9 = Merlio \| first9 = JP. \| title = Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. \| journal = Ann Oncol \| volume = 24 \| issue = 3 \| pages = 742-8 \| month = Mar \| year = 2013 \| doi = 10.1093/annonc/mds534 \| PMID = 23131393 }}</ref>

← Older revision		Revision as of 16:19, 28 December 2018
Line 24:		Line 24:
	*[[Molecular pathology tests]].		*[[Molecular pathology tests]].
	*[[KRAS mutation]].		*[[KRAS mutation]].
			*[[Ion AmpliSeq Cancer Hotspot Panel v2]].

	==References==		==References==

← Older revision		Revision as of 16:20, 28 December 2018
Line 24:		Line 24:
	*[[Molecular pathology tests]].		*[[Molecular pathology tests]].
	*[[KRAS mutation]].		*[[KRAS mutation]].
	*[[~~Ion AmpliSeq~~ Cancer Hotspot Panel v2]].		*[[Cancer Hotspot Panel v2]].

	==References==		==References==